

Atsauces uz hlrohīna un hidroksihlorohīna lietošanas novērojumu pētījumiem pacientiem ar COVID-19

1. Bessière F, Rocchia H, Delinière A et al. Assessment of QT Intervals in a Case Series of Patients with Coronavirus Disease 2019 (COVID-19) Infection Treated with Hydroxychloroquine Alone or in Combination with Azithromycin in an Intensive Care Unit. doi: 10.1001/jamacardio.2020.1787.
2. Mercurio NJ, Yen CF, Shim DJ et al. Risk of QT Interval Prolongation Associated with Use of Hydroxychloroquine with or without Concomitant Azithromycin among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). doi: 10.1001/jamacardio.2020.1834.
3. (Withdrawn) Davido B, Lansaman T, Bessis S et al. Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)? doi: 10.1101/2020.05.05.20088757.
4. Geleris J, Sun Y, Platt J et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. doi: 10.1056/NEJMoa2012410.
5. Mahévas M, Tran V-T, Roumier M et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. doi: 10.1136/bmj.m1844.
6. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. doi: 10.1016/S0140-6736(20)31180-6.
7. Million M, Lagier J-C, Gautret P et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. doi: 10.1016/j.tmaid.2020.101738.
8. Rosenberg ES, Dufort EM, Udo T et al. Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State. doi: 10.1001/jama.2020.8630.
9. Esper RB, Silva RS da, Okinawa FTC et al. Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine. self-distribution.
10. Shabrawishi MH, Naser AY, Alwafi H et al. Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions. doi: 10.1101/2020.05.08.20095679.
11. Magagnoli J, Narendran S, Pereira F et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. doi: 10.1101/2020.04.16.20065920.
12. Yu B, Li C, Chen P et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. doi: 10.1007/s11427-020-1732-2.
13. Ip A, Berry DA, Hansen E et al. Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study. doi: 10.1101/202

Vēre:

COVID-19: reminder of the risks of chloroquine and hydroxychloroquine, Press release 29/05/2020

<https://www.ema.europa.eu/en/news/covid-19-reminder-risks-chloroquine-hydroxychloroquine>